Diovan Hct
Product Images NDC 68258-6973

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Diovan Hct (NDC 68258-6973). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 68258-6972-03 (Ndc 68258 6972 03 Novartis)

Diovan HCT 160 mg/12.5 mg tablet label includes 30 tablets per container. The label lists valsartan USP 160 mg and hydrochlorothiazide USP 12.5 mg as active ingredients. Manufacturer noted as Novartis Pharmaceuticals Corp. and packaged by Dispensing Solutions, Inc. in Santa Ana, CA. The label includes warnings about use during pregnancy and advises storing at 77°F. Sample lot and expiration date 00-00 are shown along with an NDC of 68258-6972-03.*

FDA Label Image

Ndc 68258-6973-03 (Ndc 68258 6973 03 Norvatis)

Diovan HCT 160 mg/25 mg tablet label showing a 30-tablet count. Each tablet contains valsartan USP 160 mg and hydrochlorothiazide USP 25 mg. The label includes warnings about use during pregnancy, storage instructions, and dispensing details by Dispensing Solutions, Inc. Additional barcode and batch information are also visible.*

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Diovan Hct 01)

A line graph showing the effect of different drug treatments on the percentage of systolic blood pressure reduction (SBP-140 mmHg) across baseline SBP values ranging from 140 to 180 mmHg. The treatments compared include Diovan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, each represented by distinct markers and curves.*

FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Diovan Hct 02)

A line chart comparing the change in diastolic blood pressure (DBP) from baseline for Diovan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo. The x-axis represents baseline DBP in mmHg and the y-axis shows the change in DBP in mmHg, illustrating the relative efficacy of each treatment.*

FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Diovan Hct 03)

A line graph showing the relationship between baseline systolic blood pressure (SBP) in mmHg on the x-axis and the percentage of subjects with SBP below 140 mmHg on the y-axis for Diovan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo. Diovan HCT demonstrates a higher percentage of subjects achieving SBP below 140 mmHg across the baseline SBP range compared to the other treatments.*

FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Diovan Hct 04)

A line graph comparing the percentage change in baseline diastolic blood pressure (DBP) over a range of baseline DBP values (90–110 mmHg) for Diovan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. Data lines are shown for each treatment group with distinct markers.*

FDA Label Image

Valsartan Structural Formula (Diovan Hct 05)

Chemical structure of the active ingredient in Diovan HCT, showing molecular connectivity including aromatic rings, carboxyl, and amide functional groups.*

FDA Label Image

Hydrochlorothiazide Structural Formula (Diovan Hct 06)

Chemical structure diagram of the active ingredient in Diovan HCT. The structure shows a chlorinated aromatic ring with sulfonamide and other functional groups attached, representing the chemical composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.